Browse studies

Find your next paid study

4,610 recruiting studies matching your filters

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizuma…

Gastroesophageal JunctionGastroesophageal AdenocarcinomaEsophageal Neoplasms+1 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06469944

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung can…

Breast CarcinomaColorectal CarcinomaLung Non-Small Cell Carcinoma+2 more

Estimated

~$10 – $750

Wake Forest University Health SciencesNCT06418204

Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes

Objectives: 1. To examine the variations in clinical features, survival outcomes, family history, and health behavior among proband patients who are known or …

Hereditary Colorectal Cancer Syndrome

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT02863172

Phase 1

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more

Estimated

~$10 – $8,750

RayzeBio, Inc.NCT06590857

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Background: Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these inf…

Staphylococcal Infections

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT06479837

Phase 1

Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, i…

Advanced/Metastatic Colorectal Adenocarcinoma

Cognitive and Neural Mechanisms of Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder Part II: Mediation Effects

This study is a randomized controlled trial assessing the efficacy of cognitive- behavioral therapy (CBT-AR) and nutrition counseling for avoidant/restrictive …

Avoidant/Restrictive Food Intake Disorder (ARFID)

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07641205

Phase 2

A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent/Metastatic Osteosarcoma (TACOS)

This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurren…

Locally Advanced OsteosarcomaMetastatic OsteosarcomaRecurrent Osteosarcoma+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT05019703

Phase 1

Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer

The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposi…

Colorectal Adenomatous PolypColorectal CarcinomaFamilial Adenomatous Polyposis+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05630794

Observational

Multicenter, Randomized Phase II Trial on Palliative Radiation With or Without Spatially Fractionated Radiotherapy Boost for Unresectable Bulky Malignancies

This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) impr…

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmUnresectable Solid Tumor+2 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07856394

Observational

Reducing Cardiovascular Risks: The Role of Alcohol Use

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high bl…

Alcohol DrinkingDrinking BehaviorAt-risk Drinking+2 more

Estimated

~$10 – $6,250

The University of Texas at ArlingtonNCT07783061

Phase 2

Phase II Trial of Pembrolizumab in Combination With Odetiglucan for Patients With Metastatic Colorectal Adenocarcinoma With Liver Predominant Disease

This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is…

Colorectal Adenocarcinoma Metastatic in the Liver

Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT07082439